纽欧申医药
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia 2024-05-08 21:00
NeuShen Therapeutics Closes Pre-A Financing with ~$20M 2022-09-29 17:50
1